A recent study from the Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA reveals that Dystrophin (DMD) is a tumor suppressor in human cancers and myogenic programs.
This study was published in the May 4 2014 Nature Genetics (One of the top journal in Genetics with an IF of of 35.209) by Prof. Dr Jonathan A Fletcher, Yuexiang Wang and others from the Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Children’s Hospital, Boston, Massachusetts, USA; Genetic Diagnostic Laboratory, Department of Laboratory Medicine, Children’s Hospital, Boston, Massachusetts, USA; Department of Laboratory Medicine, Shanghai Children’s Medical Center, Jiaotong University, Shanghai, China; Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan; Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Molecular Diagnostics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Department of Pathology, Stanford University Medical Center, Stanford, California, USA; Department of Surgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Ludwig Center at Harvard, Harvard Medical School and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA; Enteric Neuroscience Program, Mayo Clinic, Rochester, Minnesota, USA; and Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for metastatic mesenchymal tumors (GIST, RMS and LMS): MiRNA-100 increases the expression of tumor suppressor Dystrophin (DMD) via down regulation of its target gene. This study suggests that miR-100, by increasing the expression of DMD through down regulation of its target gene, it could inhibit the proliferation of mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS). Together, this study suggests that pharmacological formulations containing miR-100 can be used to treat metastatic mesenchymal tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for metastatic mesenchymal tumors (GIST, RMS and LMS): MiRNA-100 increases the expression of tumor suppressor Dystrophin (DMD) via down regulation of its target gene, 7/June/2014, 5.19 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
